Abstract
Testicular cancer patients refractory or in relapse after primary chemotherapy have ⩽25% 5-year progression-free survival with salvage. To improve prognosis, patients entered a phase I/II tandem dose-escalation trial of carboplatin (1500–2100 mg/m2) and etoposide (1200–2250 mg/m2) with ABMT. Patients were eligible for a second cycle if disease progression was absent and performance status allowed. From August 1990 to June 1998, 29 males (25 NSGCT) were treated. At the time of ABMT, 10 were chemosensitive, four were chemoresistant, and 10 were absolutely refractory to platinum. Disease status (no. patients) at transplant: primary refractory disease (six), first relapse (10), second relapse (eight), third relapse (five). Fifteen (52%) received both transplants. Treatment-related mortality was 10%. Best response after ABMT included: two CR, one CR surgically NED, five PR, three PR surgically NED, seven SD, and eight PD. Eight (28%) patients are continuously progression-free a median 60 months (range, 31–93) from first ABMT. Three seminoma patients remain progression-free. Of five long-term NSGCT survivors, four were treated in first relapse with platinum-sensitive disease. Eighteen relapses occurred a median of 4 months after ABMT I (two late relapses at 28 and 44 months). The median PFS and OS for the whole group are 4 and 14 months, respectively. Patients with relapsed/ refractory testicular cancer benefit most from ABMT if they have platinum-sensitive disease in first relapse. Patients who do poorly despite ABMT have a mediastinal primary site, true cisplatin-refractory disease, disease progression prior to ABMT, and/or markedly elevated βHCG at ABMT. New treatment modalities are needed for the latter group. Bone Marrow Transplantation (2001) 27, 939–947.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bosl GJ, Motzer RJ . Testicular germ-cell cancer New Engl J Med 1997 337: 242–253
Parker SL, Tong T, Bolden S, Wingo PA . Cancer statistics, 1997 CA 1997 47: 5–27
Loehrer PJ, Lauer R, Roth BJ et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide Ann Int Med 1988 109: 540–546
Harstrick A, Schmoll H-J, Wilke H et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma J Clin Oncol 1991 9: 1549–1555
McCaffrey JA, Mazumdar M, Bajorin DF et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival J Clin Oncol 1997 15: 2559–2563
Loehrer PJ, Gonin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor J Clin Oncol 1998 16: 2500–2504
Birch R, Williams SD, Cone A et al. Prognostic factors for favorable outcome in disseminated germ cell tumors J Clin Oncol 1986 4: 400–407
Einhorn LH . Treatment of testicular cancer: a new and improved model (Karnofsky Memorial Lecture) J Clin Oncol 1990 8: 1777–1781
Bosl GJ, Geller NL, Cirrincione C et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer Cancer Res 1983 43: 3403–3407
Mead GM, Stenning SP, Parkinson MC et al. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors J Clin Oncol 1992 10: 85–94
International Germ Cell Cancer Collaborative Group . International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers J Clin Oncol 1997 15: 594–603
Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide New Engl J Med 1987 316: 1435–1440
Bosl GJ, Geller NL, Bajorin D et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good prognosis germ cell tumors J Clin Oncol 1988 6: 1231–1238
Einhorn LH, Williams SD, Loehrer PJ et al. Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol J Clin Oncol 1989 7: 387–391
Wozniak AJ, Samson MK, Shah NT et al. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group Study J Clin Oncol 1991 9: 70–76
Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good risk germ cell tumors: a multiinstitutional study J Clin Oncol 1993 11: 598–606
Levi JA, Raghavan D, Harvey V et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinomas J Clin Oncol 1993 11: 1300–1305
Loehrer PJ, Johnson D, Elson P et al. Importance of bleomycin in favorable-prognosis germ cell tumors: an Eastern Cooperative Oncology Group trial J Clin Oncol 1995 13: 470–476
De Wit R, Stoter G, Kaye SB et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group J Clin Oncol 1997 15: 1837–1843
Horwich A, Sleijfer DT, Fossa SD et al. Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial J Clin Oncol 1997 15: 1844–1852
Saxman SB, Finch D, Gonin R, Einhorn LH . Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin in favorable-prognosis germ cell tumors: the Indiana University Experience J Clin Oncol 1998 16: 702–706
Nichols CR, Tricot G, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer – a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation J Clin Oncol 1989 7: 932–939
Adams PT, Ayash L, Ratanatharathorn V et al. Phase I/II high-dose chemotherapy with autologous stem cell support for testis cancer: the University of Michigan experience Proc Am Soc Clin Oncol 1998 17: 325a (Abstr. 1252)
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Armitage P, Berry G . Statistical Methods in Medical Research (2nd edn) Blackwell Scientific: Oxford 1987
Fleming ID, Cooper JS, Henson DE et al (eds). AJCC Cancer Staging Handbook Lippincott-Raven: Philadelphia, PA 1998
Skipper HE . Combination therapy: some concepts and results Cancer Chemother Rep 1974 4: 137–145
Frei E, Cucchi C, Rosowsky A et al. Alkylating agent resistance: in vitro studies of human cell lines Proc Natl Acad Sci USA 1985 82: 2158–2162
Teicher B, Cucchi C, Lee J et al. Alkylating agents: in vitro studies of cross-resistance patterns in human tumor cell lines Cancer Res 1986 46: 4379–4383
Schabel F . Patterns of resistance and therapeutic synergism among alkylating agents Fund Cancer Chemother 1978 23: 200–215
Schabel F, Griswold D, Corbett T . Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology Cancer 1984 54 (Suppl. 6): 1160–1167
Holden SA, Teicher B, Ayash LJ et al. A preclinical model for sequential high-dose chemotherapy Cancer Chemother Pharmacol 1995 36: 61–64
Nichols CR, Tricot PJ, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer – a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation J Clin Oncol 1989 7: 932–939
Nichols CR, Andersen J, Lazarus HM et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol J Clin Oncol 1992 10: 558–563
Broun ER, Nichols CR, Kneebone P et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue Ann Int Med 1992 117: 124–128
Broun ER, Nichols CR, Turns M et al. Early salvage therapy for germ cell cancer using high-dose chemotherapy with autologous bone marrow support Cancer 1994 73: 1716–1720
Broun ER, Nichols CR, Gize G et al. Tandem high-dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer Cancer 1997 79: 1605–1610
Motzer RJ, Bosl GJ . High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions J Natl Cancer Inst 1992 84: 1703–1709
Motzer RJ, Gulati SC, Crown JP et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors Cancer 1992 69: 550–556
Motzer RJ, Mazumdar M, Bosl GJ et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity J Clin Oncol 1996 14: 1098–1105
Lotz JP, Machover D, Malassagne B et al. Phase I–II study of two consecutive courses of high-dose epipodophyllotoxic, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors J Clin Oncol 1991 9: 1860–1870
Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables J Clin Oncol 1996 14: 2638–2645
Rodenhuis S, van der Wall E, ten Bokkel Huinink WW et al. Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer Cancer Invest 1995 13: 355–362
Droz JP, Pico JL, Ghosn M et al. Long-term survivors after salvage high-dose chemotherapy with bone marrow rescue in refractory germ cell cancer Eur J Cancer 1991 27: 831–835
Siegert W, Beyer J, Strohscheer I et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study J Clin Oncol 1994 12: 1223–1231
Lotz JP, Andre T, Donsimoni R et al. High-dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults Cancer 1995 75: 874–885
Margolin K, Doroshow JH, Ahn C et al. Treatment with germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem cell support J Clin Oncol 1996 14: 2631–2637
Broun ER, Nichols CR, Tricot PJ et al. High-dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors Bone Marrow Transplant 1991 7: 53–56
Bhatia S, Cornetta K, Broun ER et al. High-dose chemotherapy with peripheral stem cell or autologous bone marrow transplant as initial salvage chemotherapy for testicular cancer Proc Am Soc Clin Oncol 1998 17: 321a (Abstr. 1239)
Barnett MJ, Coppin CML, Murray N et al. High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumors Br J Cancer 1993 68: 594–598
Motzer RJ, Mazumdar M, Bajorin DF et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors J Clin Oncol 1997 15: 2546–2552
Matthay KK, Villablanca JG, Seeger RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid New Engl J Med 1999 341: 1165–1173
Iida K, Kawai K, Hayashi H et al. Cases of refractory testicular cancer treated with all-trans-retinoic acid Jap J Cancer Chemother 1999 26: 841–844
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ayash, L., Clarke, M., Silver, S. et al. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review. Bone Marrow Transplant 27, 939–947 (2001). https://doi.org/10.1038/sj.bmt.1703008
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703008
Keywords
This article is cited by
-
High-dose chemotherapy for relapsed testicular germ cell tumours
Nature Reviews Urology (2023)
-
Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies
Medical Oncology (2017)
-
Long-term follow-up of patients undergoing auto-SCT for advanced germ cell tumour: a multicentre cohort study
Bone Marrow Transplantation (2011)
-
Autoimmune thrombocytopenia following tandem autologous peripheral blood stem cell transplantation for refractory germ cell tumor
Bone Marrow Transplantation (2004)